Company: SCLXW
Filing Date: 2025-12-16
Form Type: S-1
Source: 0001193125-25-319720
Chunk: 30

Company: Scilex Holding Co
Filing Date: 2025-12-16
Form: S-1
Chunk 30
---
 our common stock outstanding immediately after giving effect to such conversion. The Exchange Warrant Maximum Percentage may be raised or lowered to any other percentage not in excess of 9.99%, at the option of the holder, except that any increase will only be effective upon 61 days’ prior notice to us.Exercise PeriodThe Exchange Warrants were immediately exercisable upon issuance and will continue to be exercisable until the expiration of the Exchange Warrants on October 8, 2029.Use of proceedsWe will receive up to an aggregate of approximately $20.0 million from the exercise of the Exchange Warrants, assuming the exercise in full of all of the Exchange Warrants for cash. The Exchange Warrants are exercisable at a price of $40.00 per share. On December 12, 2025, the closing price for our Common Stock was $16.63 per share. If the price of our Common Stock remains below $40.00 per share, we believe the Tranche B Investors will be unlikely to cash exercise their Exchange Warrants, resulting in little or no cash proceeds to us.We expect to use the net proceeds from the exercise of the Exchange Warrants for cash for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. See “Use of Proceeds” elsewhere in this prospectus.Certain U.S. Federal Income Tax ConsiderationsYou should consult your tax advisor with respect to the U.S. federal income tax consequences of owning the Exchange Warrants or any18

#### shares of common stock that may be issued upon exercise of the Exchange Warrants in light of your own particular situation and with respect to any tax consequences arising under the laws of any state, local, foreign or other taxing jurisdiction. See “Material U.S. Federal Income Tax Considerations of the Notes and Warrants” in this prospectus.Resale of Common Stock by the Selling StockholdersShares of Common Stock offered by the Selling SecurityholdersUp to 1,703,946 shares of our Common Stock consisting of (i) 275,000 September 2025 Warrant Shares and (ii) 1,428,946 November 2025 Warrant Shares.Use of proceedsWe will not receive any proceeds from the sale of shares of Common Stock by the Selling Stockholders, except with respect to amounts received by us upon the exercise of the